Omeros Revenue

Revenue (ttm)

n/a

Revenue Growth

n/a

P/S Ratio

n/a

Revenue / Employee

n/a

Employees

202

Market Cap

524.37M

Revenue Chart

Revenue History

Fiscal Year End	Revenue	Change	Growth
Dec 31, 2024	-	-	-
Dec 31, 2023	-	-	-
Dec 31, 2022	-	-	-
Dec 31, 2021	-	-	-
Dec 31, 2020	-	-	-
Dec 31, 2019	Upgrade Pro	Upgrade Pro	Upgrade Pro
Dec 31, 2018	Upgrade Pro	Upgrade Pro	Upgrade Pro
Dec 31, 2017	Upgrade Pro	Upgrade Pro	Upgrade Pro
Dec 31, 2016	Upgrade Pro	Upgrade Pro	Upgrade Pro
Dec 31, 2015	Upgrade Pro	Upgrade Pro	Upgrade Pro

Revenue Definition

Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.

Full Definition

Related Stocks

Company Name	Revenue
UnitedHealth Group	422.82B
Johnson & Johnson	92.15B
Merck & Co.	63.62B
AbbVie	58.33B
AstraZeneca	56.50B
Novartis AG	55.19B
Eli Lilly and Company	53.26B
Novo Nordisk	49.11B

Revenue Rankings

OMER News

11 days ago - Omeros: Novo Nordisk Deal Highlights MASP-3 Alternative Pathway Targeting - Seeking Alpha
13 days ago - Omeros: Novo Nordisk's Licensing Deal Sends Shares Soaring, Makes Bull Case - Seeking Alpha
13 days ago - Omeros Announces Publication Highlighting Survival Benefits in TA-TMA Patients Treated with Narsoplimab Versus a Well-Matched External Control Group - Business Wire
14 days ago - Omeros Stock Skyrockets After Novo Nordisk Strikes $2.1B Rare Disease Drug Deal - Benzinga
14 days ago - Can OMER stock retain Novo Nordisk driven gains over the long-term? - Invezz
14 days ago - Novo Nordisk to Pay Omeros Up to $2.1 Billion For Blood Disease Drug - WSJ
14 days ago - Novo Nordisk signs up to $2.1 billion licensing deal with Omeros in rare disease push - Reuters
14 days ago - Novo Nordisk and Omeros announce asset purchase and license agreement for Omeros' clinical-stage MASP-3 inhibitor zaltenibart (OMS906) - GlobeNewsWire

More News